Africa receives drugs and vaccines but not devices, diagnostics, or digital health.
Drug Trials (%)
68%
Device Trials
4%
Diagnostic Trials
6%
Digital Health
2%
Key Finding
Drug trials dominated Africa's portfolio, while device trials represented under five percent and digital health interventions numbered only 268 compared to 4,540 in the United States (17x gap).
Regional Comparison
Cancer — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Cancer — Computed Statistics
Africa: 2,182 | US: 49,054 | Europe: 28,724 | Ratio: 22.5x
Africa share: 2.7% | HHI4-region = 0.565 | Shannon H = 1.6 bits
Immunotherapy: AF 92 vs US 3,803 (41.3x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Africa's trial portfolio is dominated by drugs (68%) and vaccines (14%), while devices, diagnostics, and digital health together account for barely 12%. In contrast, high-income countries test a balanced portfolio of intervention types. This modality asymmetry means Africa is a recipient of pharmaceutical innovation but excluded from the surgical, diagnostic, and digital health revolutions transforming global medicine.
The Evidence 150 words · target 156
In health technology assessment, does the distribution of intervention types in African trials show a modality imbalance compared to global portfolios? This audit classified 23,873 African trials by intervention modality using ClinicalTrials.gov keyword analysis for drugs, devices, diagnostics, digital health, and behavioural interventions through March 2026. Investigators reported the modality concentration index as the primary estimand for innovation diversity. Drug trials dominated Africa's portfolio, while device trials represented under five percent and digital health interventions numbered only 268 compared to 4,540 in the United States (17x gap). Immunotherapy trials were virtually absent in Africa (92) compared to 3,803 in the United States, a 41x disparity. Africa receives pharmaceutical validation but is excluded from the device, diagnostic, and digital health revolutions transforming high-income healthcare. These findings reveal a structural modality asymmetry that limits the type of health innovations accessible to African populations. Interpretation is limited by keyword-based classification of intervention modalities.
Sentence Structure
Question
In health technology assessment, does the distribution of intervention types in African trials show a modality imbalance compared to global portfolios?
Dataset
This audit classified 23,873 African trials by intervention modality using ClinicalTrials.gov keyword analysis for drugs, devices, diagnostics, digital health, and behavioural interventions through March 2026.
Method
Investigators reported the modality concentration index as the primary estimand for innovation diversity.
Primary Result
Drug trials dominated Africa's portfolio, while device trials represented under five percent and digital health interventions numbered only 268 compared to 4,540 in the United States (17x gap).
Robustness
Immunotherapy trials were virtually absent in Africa (92) compared to 3,803 in the United States, a 41x disparity.
Interpretation
Africa receives pharmaceutical validation but is excluded from the device, diagnostic, and digital health revolutions transforming high-income healthcare.
Boundary
These findings reveal a structural modality asymmetry that limits the type of health innovations accessible to African populations.